BioLineRx Ltd. (NASDAQ:BLRX)‘s stock had its “buy” rating restated by investment analysts at Oppenheimer Holdings, Inc. in a research report issued to clients and investors on Tuesday. They presently have a $3.00 target price on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price objective suggests a potential upside of 183.02% from the company’s current price. Oppenheimer Holdings also issued estimates for BioLineRx’s FY2021 earnings at $0.06 EPS.
A number of other equities analysts have also commented on BLRX. Maxim Group set a $3.00 price objective on BioLineRx and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Roth Capital set a $3.00 price objective on BioLineRx and gave the stock a “buy” rating in a research note on Wednesday, August 9th. HC Wainwright set a $4.00 price objective on BioLineRx and gave the stock a “buy” rating in a research note on Saturday, June 3rd. ValuEngine lowered BioLineRx from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Finally, Zacks Investment Research lowered BioLineRx from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $2.59.
Shares of BioLineRx (NASDAQ BLRX) opened at 1.06 on Tuesday. The company’s market capitalization is $101.35 million. The company’s 50-day moving average price is $1.07 and its 200-day moving average price is $0.97. BioLineRx has a 1-year low of $0.80 and a 1-year high of $1.42.
BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.05). On average, equities analysts expect that BioLineRx will post ($0.24) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “BioLineRx Ltd. (BLRX) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.” was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://transcriptdaily.com/2017/09/14/biolinerx-ltd-blrx-stock-rating-reaffirmed-by-oppenheimer-holdings-inc.html.
Institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC lifted its stake in BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares during the period. Renaissance Technologies LLC acquired a new position in BioLineRx in the first quarter valued at approximately $126,000. Benchmark Capital Advisors lifted its stake in BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 100,000 shares during the period. KCG Holdings Inc. lifted its stake in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares during the period. Finally, Sabby Management LLC acquired a new position in BioLineRx in the first quarter valued at approximately $3,018,000. 32.27% of the stock is currently owned by hedge funds and other institutional investors.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.